Results 81 to 90 of about 59,343,149 (303)

Reasons for Cannabis use in Psychosis [PDF]

Australian & New Zealand Journal of Psychiatry, 2006
Objective: To examine the reasons for cannabis use among individuals with psychotic disorders. Method: Forty-nine people with psychotic disorders in treatment with community health centres in Northern Sydney were interviewed to collect information about their experience of antipsychotic side-effects and their influence on cannabis use.
David, Schofield, Chris, Tennant, Louise, Nash, Louisa, Degenhardt, Alison, Cornish, Coletta, Hobbs, Gail, Brennan   +6 more
openaire   +2 more sources

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar, Daniela Gorski, Marcela Harumi Kagueiama, Astrid Wiens   +3 more
wiley   +1 more source

An ETH‐LAD trip with unfavourable consequences: A case report

British Journal of Clinical Pharmacology, EarlyView.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH‐LAD (6‐ethyl‐6‐nor‐lysergic acid diethylamide), the N‐ethyl derivative of LSD.
Johannes Nadler, Michaela Sommer, Annette Zschiesche, Anne Stürzebecher, Christina Grumann, Volker Auwärter, Maren Hermanns‐Clausen   +6 more
wiley   +1 more source

Available but inaccessible: patient experiences during the first 2 years of a primary care-based medical cannabis program at an academic medical center

Harm Reduction Journal
Background Medical cannabis use and public acceptance in the United States have increased over the past 25 years. However, access to medical cannabis remains limited, particularly for underserved populations. To understand how patients experience medical
Eloise W. Freitag, Yuval Zolotov, Jayabhargav Annam, Jaqueline Labins, Jaclyn M. Yamada, Syeda Masharab Jillani, Julia H. Arnsten, Deepika E. Slawek   +7 more
doaj   +1 more source

A large-scale genome-wide association study meta-analysis of cannabis use disorder

Lancet psychiatry, 2020
Summary Background Variation in liability to cannabis use disorder has a strong genetic component (estimated twin and family heritability about 50–70%) and is associated with negative outcomes, including increased risk of psychopathology.
E. Johnson, D. Demontis, T. Thorgeirsson, R. Walters, R. Polimanti, A. Hatoum, S. Sanchez-Roige, S. Paul, F. Wendt, Toni‐Kim Clarke, D. Lai, Gunnar W. Reginsson, Hang Zhou, June He, D. Baranger, D. Gudbjartsson, Robbee Wedow, D. Adkins, Amy E Adkins, Jeffry C. Alexander, S. Bacanu, T. Bigdeli, J. Boden, Sandy Brown, K. Bucholz, J. Bybjerg-Grauholm, R. Corley, L. Degenhardt, D. Dick, Benjamin Domingue, Louis Fox, A. Goate, Scott D. Gordon, L. Hack, D. Hancock, Sarah M. Hartz, I. Hickie, D. Hougaard, K. Krauter, P. Lind, J. McClintick, M. McQueen, J. Meyers, G. Montgomery, O. Mors, P. Mortensen, M. Nordentoft, J. Pearson, Roseann E. Peterson, M. Reynolds, John P. Rice, V. Rúnarsdóttir, N. Saccone, R. Sherva, J. Silberg, R. Tarter, Thorarinn Tyrfingsson, T. Wall, B. Webb, T. Werge, L. Wetherill, Margaret J. Wright, S. Zellers, M. Adams, L. Bierut, J. Boardman, William E. Copeland, L. Farrer, T. Foroud, N. Gillespie, R. Grucza, K. Harris, A. Heath, V. Hesselbrock, J. Hewitt, Christian J. Hopfer, J. Horwood, W. Iacono, E. Johnson, K. Kendler, M. Kennedy, H. Kranzler, P. Madden, H. Maes, B. Maher, N. Martin, M. McGue, A. McIntosh, S. Medland, E. Nelson, B. Porjesz, B. Riley, M. Stallings, M. Vanyukov, S. Vrieze, L. Davis, R. Bogdan, J. Gelernter, H. Edenberg, K. Stefánsson, A. Børglum, A. Agrawal   +101 more
semanticscholar   +1 more source

Demographic, Cannabis Use, and Depressive Correlates of Cannabis Use Consequences in Regular Cannabis Users

The American Journal on Addictions, 2019
Background and ObjectivesRegular cannabis users experience cannabis‐related consequences across many domains of functioning. The present study examined demographic, cannabis use, and depressive correlates of cannabis consequences. We hypothesized that (1) earlier onset of use would predict greater psychological and functional consequences; and (2 ...
Cara A. Struble, Jennifer D. Ellis, Molly Cairncross, Jamey J. Lister, Leslie H. Lundahl   +4 more
openaire   +3 more sources

Cannabis Use and Suicidal Ideation [PDF]

SSRN Electronic Journal, 2012
Globally, suicide has emerged as the second leading cause of death among youth aged 10-24 years old. In order to better understand the causes of this phenomenon, we investigate the relationship between suicidal ideation and cannabis use. Our empirical analysis is based on a 30-year longitudinal study of a birth cohort.
van Ours, J.C., Williams, J.E., Fergusson, D., Horwood, L.J.   +3 more
openaire   +7 more sources

Breaking point: Identifying the factors that predict suspension from school

British Educational Research Journal, EarlyView.
Abstract School suspensions are associated with adverse educational and psychosocial outcomes, yet little is known about how structural disadvantage, relational factors, health behaviours, well‐being indicators and school‐level factors jointly predict suspension risk in England.
Stephanie Cahill, Roberto Vagnetti, Christopher Knowles, Emma Thornton, Qiqi Cheng, Neil Humphrey   +5 more
wiley   +1 more source

Associations between recreational cannabis legalization and cannabis use disorder treatment outcomes in California, 2010–2021

Journal of Cannabis Research
Background Despite extensive research on the broader effects of recreational cannabis legalization (RCL), limited attention has been given to its impact on cannabis use disorder (CUD) treatment outcomes.
Brittany Bass, Howard Padwa, Dhruv Khurana, Darren Urada   +3 more
doaj   +1 more source